Table 2 Clinical characteristics of 478... | American Society of Hematology

Table 2

Clinical characteristics of 478 de novo DLBCL and multivariate survival analysis

A. Clinical characteristics of patients with de novo DLBCL treated with R-CHOP: comparison between patients with or without MDM2 overexpression or with different SNP309 genotypes

	Overall (n = 478)			WT-p53 (n = 372)			MUT-p53 (n = 106)			SNP (n = 108)
	MDM2^–	MDM2⁺	P	MDM2^–	MDM2⁺	P	MDM2^–	MDM2⁺	P	T/T	T/G or G/G	P
n	285	193		216	156		69	37		41	67
Age, y
<60	124	68		95	56		29	12		17	22
≥60	161	125	.07	121	100	.12	40	25	.33	24	45	.37
Gender
F	128	69		97	57		31	12		10	23
M	157	124	.046	119	99	.11	38	25	.21	31	44	.28
Stage
I-II	136	79		101	67		35	12		17	25
III-IV	137	108	.11	103	83	.37	34	25	.071	24	49	.41
B-symptoms
No	158	123		118	101		40	22		26	45
Yes	80	51	.35	63	40	.22	17	11	.73	12	18	.75
LDH
Normal	83	64		69	52		14	12		14	19
Elevated	180	103	.17	130	80	.50	50	23	.23	18	30	.82
No. of extranodal sites
0-1	217	138		164	111		53	27		41	52
≥2	55	45	.27	41	36	.31	14	9	.63	0	15	.0011
Performance status
0-1	218	137		163	108		55	29		28	47
≥2	30	27	.21	23	23	.20	7	4	.90	5	8	.94
Size of largest tumor
<5 cm	131	87		101	75		30	12		22	33
≥5 cm	88	62	.78	63	45	.88	25	17	.25	8	18	.42
IPI risk group
0-2	170	99		130	78		40	21		25	36
3-5	83	71	.064	61	57	.062	22	14	.67	10	20	.50
Therapy response
CR	225	139	.081	176	123	.53	49	16	.0051	28	49	.59
PR	33	30		22	20		11	10		7	9
SD	13	4		8	3		5	1		1	1
PD	14	20		10	10		4	10		5	8

	Overall (n = 478)			WT-p53 (n = 372)			MUT-p53 (n = 106)			SNP (n = 108)
	MDM2^–	MDM2⁺	P	MDM2^–	MDM2⁺	P	MDM2^–	MDM2⁺	P	T/T	T/G or G/G	P
n	285	193		216	156		69	37		41	67
Age, y
<60	124	68		95	56		29	12		17	22
≥60	161	125	.07	121	100	.12	40	25	.33	24	45	.37
Gender
F	128	69		97	57		31	12		10	23
M	157	124	.046	119	99	.11	38	25	.21	31	44	.28
Stage
I-II	136	79		101	67		35	12		17	25
III-IV	137	108	.11	103	83	.37	34	25	.071	24	49	.41
B-symptoms
No	158	123		118	101		40	22		26	45
Yes	80	51	.35	63	40	.22	17	11	.73	12	18	.75
LDH
Normal	83	64		69	52		14	12		14	19
Elevated	180	103	.17	130	80	.50	50	23	.23	18	30	.82
No. of extranodal sites
0-1	217	138		164	111		53	27		41	52
≥2	55	45	.27	41	36	.31	14	9	.63	0	15	.0011
Performance status
0-1	218	137		163	108		55	29		28	47
≥2	30	27	.21	23	23	.20	7	4	.90	5	8	.94
Size of largest tumor
<5 cm	131	87		101	75		30	12		22	33
≥5 cm	88	62	.78	63	45	.88	25	17	.25	8	18	.42
IPI risk group
0-2	170	99		130	78		40	21		25	36
3-5	83	71	.064	61	57	.062	22	14	.67	10	20	.50
Therapy response
CR	225	139	.081	176	123	.53	49	16	.0051	28	49	.59
PR	33	30		22	20		11	10		7	9
SD	13	4		8	3		5	1		1	1
PD	14	20		10	10		4	10		5	8

View Large

This Feature Is Available To Subscribers Only